55 related articles for article (PubMed ID: 23379516)
21. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
Nissinen R; Leirisalo-Repo M; Peltomaa R; Palosuo T; Vaarala O
Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
[TBL] [Abstract][Full Text] [Related]
22. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression.
Aerts NE; De Knop KJ; Leysen J; Ebo DG; Bridts CH; Weyler JJ; Stevens WJ; De Clerck LS
Rheumatology (Oxford); 2010 Dec; 49(12):2264-72. PubMed ID: 20724433
[TBL] [Abstract][Full Text] [Related]
23. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
Odai T; Matsunawa M; Takahashi R; Wakabayashi K; Isozaki T; Yajima N; Miwa Y; Kasama T
J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
[TBL] [Abstract][Full Text] [Related]
24. Blockage of TNF-α by infliximab reduces CCL2 and CCR2 levels in patients with rheumatoid arthritis.
Xia L; Lu J; Xiao W
J Investig Med; 2011 Aug; 59(6):961-3. PubMed ID: 21527853
[TBL] [Abstract][Full Text] [Related]
25. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
26. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis.
Eriksson C; Rantapää-Dahlqvist S; Sundqvist KG
Scand J Rheumatol; 2013; 42(4):260-5. PubMed ID: 23379516
[TBL] [Abstract][Full Text] [Related]
27. Dose optimization of infliximab in patients with rheumatoid arthritis.
Alten R; van den Bosch F
Int J Rheum Dis; 2014 Jan; 17(1):5-18. PubMed ID: 24472261
[TBL] [Abstract][Full Text] [Related]
28. [Treatment for rheumatoid arthritis by chemokine blockade].
Nanki T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):172-80. PubMed ID: 27320932
[TBL] [Abstract][Full Text] [Related]
29. Chemokines and chemokine receptors as promising targets in rheumatoid arthritis.
Murayama MA; Shimizu J; Miyabe C; Yudo K; Miyabe Y
Front Immunol; 2023; 14():1100869. PubMed ID: 36860872
[TBL] [Abstract][Full Text] [Related]
30. Chemokines and chemokine receptors in rheumatoid arthritis.
Szekanecz Z; Kim J; Koch AE
Semin Immunol; 2003 Feb; 15(1):15-21. PubMed ID: 12495637
[TBL] [Abstract][Full Text] [Related]
31. Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis.
Wu C; Wang S; Xian P; Yang L; Chen Y; Mo X
Biomed Res Int; 2016; 2016():7185708. PubMed ID: 27556040
[TBL] [Abstract][Full Text] [Related]
32. [Biomarkers for prognosis of response to anti-TNF therapy of rheumatoid arthritis: Where do we stand?].
Stuhlmüller B; Skriner K; Häupl T
Z Rheumatol; 2015 Nov; 74(9):812-8. PubMed ID: 26347122
[No Abstract] [Full Text] [Related]
33. Chemokines and chemokine receptors in arthritis.
Szekanecz Z; Vegvari A; Szabo Z; Koch AE
Front Biosci (Schol Ed); 2010 Jan; 2(1):153-67. PubMed ID: 20036936
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
